Apotex Can't Sink Amgen's IP Suit Over Drugs To Aid Chemo
Amgen can move forward with allegations that Apotex infringed a patent covering its chemotherapy-easing drugs Neupogen and Neulasta after a Florida federal judge ruled that it was too early to find...To view the full article, register now.
Already a subscriber? Click here to view full article